CBA

CBA Pharma is a biopharmaceutical company based in Lexington, Kentucky, that was founded in 1999 to develop drugs targeting multidrug resistance (MDR) in cancer. The company's primary candidate was CBT-1 (tetrandrine), an orally administered small molecule P-glycoprotein (P-gp) inhibitor designed to be used as an adjunct to chemotherapy to prevent or reverse drug resistance. CBT-1 was evaluated in multiple clinical trials, including Phase 2 and Phase 3 studies, for indications such as acute myeloid leukemia, breast cancer, and non-small cell lung cancer. However, the company failed to demonstrate the drug's efficacy to the FDA, leading to the withdrawal of its New Drug Application (NDA) in April 2023. In February 2026, the SEC charged CBA Pharma and its executives with defrauding investors by falsely claiming that CBT-1 was highly effective and on the verge of FDA approval, and the company is currently out of business.